Pharma Foods International Past Earnings Performance
Past criteria checks 4/6
Pharma Foods International has been growing earnings at an average annual rate of 22.6%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 30.1% per year. Pharma Foods International's return on equity is 27.7%, and it has net margins of 5.2%.
Key information
22.6%
Earnings growth rate
22.9%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | 30.1% |
| Return on equity | 27.7% |
| Net Margin | 5.2% |
| Next Earnings Update | 11 Dec 2024 |
Recent past performance updates
Recent updates
Pharma Foods International Co., Ltd.'s (TSE:2929) Prospects Need A Boost To Lift Shares
Oct 31
We Think Pharma Foods International's (TSE:2929) Solid Earnings Are Understated
Sep 22Is Pharma Foods International (TSE:2929) Using Too Much Debt?
Jul 23We Like Pharma Foods International's (TSE:2929) Earnings For More Than Just Statutory Profit
Mar 23Revenue & Expenses Breakdown
How Pharma Foods International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 62,147 | 3,205 | 42,561 | 978 |
| 30 Apr 24 | 63,210 | 3,869 | 43,987 | 946 |
| 31 Jan 24 | 65,081 | 4,763 | 44,956 | 909 |
| 31 Oct 23 | 67,684 | 5,187 | 46,776 | 911 |
| 31 Jul 23 | 68,572 | 3,081 | 50,757 | 840 |
| 30 Apr 23 | 68,668 | 978 | 52,449 | 890 |
| 31 Jan 23 | 66,507 | -2,849 | 54,361 | 869 |
| 31 Oct 22 | 64,609 | -3,425 | 53,051 | 827 |
| 31 Jul 22 | 60,185 | -374 | 46,211 | 766 |
| 30 Apr 22 | 57,054 | 2,004 | 41,601 | 643 |
| 31 Jan 22 | 55,180 | 5,848 | 37,015 | 622 |
| 31 Oct 21 | 50,971 | 6,499 | 34,076 | 570 |
| 31 Jul 21 | 46,752 | 3,841 | 33,486 | 522 |
| 30 Apr 21 | 37,989 | 2,437 | 27,909 | 462 |
| 31 Jan 21 | 29,294 | 1,780 | 21,643 | 419 |
| 31 Oct 20 | 20,650 | 45 | 16,179 | 457 |
| 31 Jul 20 | 15,353 | 690 | 10,900 | 437 |
| 30 Apr 20 | 13,776 | 377 | 9,931 | 419 |
| 31 Jan 20 | 11,796 | -791 | 9,624 | 400 |
| 31 Oct 19 | 11,047 | 99 | 8,272 | 323 |
| 31 Jul 19 | 10,532 | 499 | 7,601 | 317 |
| 30 Apr 19 | 9,893 | 435 | 7,294 | 302 |
| 31 Jan 19 | 9,458 | 911 | 6,448 | 298 |
| 31 Oct 18 | 8,905 | 390 | 6,450 | 287 |
| 31 Jul 18 | 7,943 | 313 | 5,743 | 274 |
| 30 Apr 18 | 7,239 | 88 | 5,434 | 264 |
| 31 Jan 18 | 6,386 | -259 | 5,084 | 239 |
| 31 Oct 17 | 5,457 | 66 | 4,033 | 235 |
| 31 Jul 17 | 4,722 | 101 | 3,366 | 241 |
| 30 Apr 17 | 4,335 | 119 | 3,009 | 251 |
| 31 Jan 17 | 3,786 | -50 | 2,691 | 283 |
| 31 Oct 16 | 3,698 | -61 | 2,488 | 319 |
| 31 Jul 16 | 3,460 | 25 | 2,192 | 313 |
Quality Earnings: 2929 has high quality earnings.
Growing Profit Margin: 2929's current net profit margins (5.2%) are higher than last year (4.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2929's earnings have grown significantly by 22.6% per year over the past 5 years.
Accelerating Growth: 2929's earnings growth over the past year (4%) is below its 5-year average (22.6% per year).
Earnings vs Industry: 2929 earnings growth over the past year (4%) exceeded the Biotechs industry 4%.
Return on Equity
High ROE: Whilst 2929's Return on Equity (27.67%) is high, this metric is skewed due to their high level of debt.